0 avis
THERAPEUTIC EFFECTS OF CHLORZOXAZONE, A BKCA CHANNEL AGONIST, IN A MOUSE MODEL OF FRAGILE X SYNDROME
Archive ouverte
Edité par CCSD -
International audience. BACKGROUND Fragile X Syndrome (FXS) is the most common form of inherited intellectual disability and the main monogenic cause of autism Calcium-dependent potassium (BKCa) channels have been proposed as a pharmacological target for FXS (Hebert, Pietropaolo et al. 2014) Chlorzoxazone is a FDA-approved BKCa agonist used for muscular pathologies, recently suggested for neuropsychiatric diseases AIMS Evaluate the therapeutic efficacy of Chlorzoxazone (CHLOR) on the FXS-like alterations of Fmr1-KO mice Compare the efficacy of CHLOR in both acute and chronic approaches with metformin (MET), an anti-diabetes medication acting on MMP-9 and suggested for FXS (Gantois et al. 2017)